Last reviewed · How we verify
HBV-MPL vaccine Formulation A — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
HBV-MPL vaccine Formulation A (HBV-MPL vaccine Formulation A) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HBV-MPL vaccine Formulation A TARGET | HBV-MPL vaccine Formulation A | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HBV-MPL vaccine Formulation A CI watch — RSS
- HBV-MPL vaccine Formulation A CI watch — Atom
- HBV-MPL vaccine Formulation A CI watch — JSON
- HBV-MPL vaccine Formulation A alone — RSS
Cite this brief
Drug Landscape (2026). HBV-MPL vaccine Formulation A — Competitive Intelligence Brief. https://druglandscape.com/ci/hbv-mpl-vaccine-formulation-a. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab